Cost-effectiveness analysis of fluzoparib monotherapy versus combination with apatinib in the treatment of germline <italic style="font-style: italic">BRCA1</italic>/<italic style="font-style: italic">2</italic>-mutated HER2-negative metastatic breast cancer

WANG Liyuan; ZHANG Lingli; HOU Yanhong

doi:10.6039/j.issn.1001-0408.2026.14.11

您当前的位置：

首页 >

文章列表页 >

Cost-effectiveness analysis of fluzoparib monotherapy versus combination with apatinib in the treatment of germline BRCA1/2-mutated HER2-negative metastatic breast cancer

更新时间：2026-07-28

- Cost-effectiveness analysis of fluzoparib monotherapy versus combination with apatinib in the treatment of germline BRCA1/2-mutated HER2-negative metastatic breast cancer
- ZHONGGUO YAOFANG Vol. 37, Issue 14, Pages: 1862-1867(2026)
- 作者机构：
  
  中国药科大学国际医药商学院，南京　211198
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2026.14.11
  CLC： R956
- Received：08 January 2026，
  
  Revised：2026-07-13，
  
  Accepted：13 July 2026，
  
  Online First：24 July 2026，
  
  Published：30 July 2026
- 稿件说明：
移动端阅览
王丽媛,张伶俐,侯艳红.氟唑帕利单药对比联合阿帕替尼治疗胚系BRCA1/2突变的HER2－转移性乳腺癌的成本-效用分析 [J].中国药房,2026,37(14):1862-1867.

WANG Liyuan,ZHANG Lingli,HOU Yanhong.Cost-effectiveness analysis of fluzoparib monotherapy versus combination with apatinib in the treatment of germline BRCA1/2-mutated HER2-negative metastatic breast cancer[J].ZHONGGUO YAOFANG,2026,37(14):1862-1867.
王丽媛,张伶俐,侯艳红.氟唑帕利单药对比联合阿帕替尼治疗胚系BRCA1/2突变的HER2－转移性乳腺癌的成本-效用分析 [J].中国药房,2026,37(14):1862-1867. DOI： 10.6039/j.issn.1001-0408.2026.14.11.

WANG Liyuan,ZHANG Lingli,HOU Yanhong.Cost-effectiveness analysis of fluzoparib monotherapy versus combination with apatinib in the treatment of germline BRCA1/2-mutated HER2-negative metastatic breast cancer[J].ZHONGGUO YAOFANG,2026,37(14):1862-1867. DOI： 10.6039/j.issn.1001-0408.2026.14.11.

摘要

目的

从我国卫生体系视角，评价氟唑帕利单药对比联合阿帕替尼用于伴有胚系

BRCA1

突变的人表皮生长因子受体2阴性（HER2－）转移性乳腺癌二线及后线治疗的经济性。

方法

基于FABULOUS研究，建立分区生存模型模拟疾病进展过程，模拟周期为21 d，研究时限为10年，贴现率为4.5%。模型以质量调整生命年（QALYs）及总成本作为产出评价指标，采用成本-效用分析法进行分析，通过比较两种方案的增量成本-效果比（ICER）和意愿支付（WTP）阈值来评价方案经济性。WTP阈值设为2025年我国2倍人均GDP（199 330元/QALY）。通过单因素敏感性分析、概率敏感性分析和情境分析以检验模型稳健性。

结果

对于伴有胚系

BRCA1

突变的HER2－转移性乳腺癌患者，使用氟唑帕利联合阿帕替尼方案较氟唑帕利单药方案可获得更多健康获益（1.91 QALYs vs. 1.69 QALYs），同时总成本更低（1 634 119.3元vs. 1 855 264.2元），为绝对优势方案。单因素及概率敏感性分析结果表明基础分析结果稳健。情境分析结果中，变动研究时限为5年或将贴现率调整为3%，基础分析结论均保持稳健；但当变动外推分布模型时，结果发生翻转。

结论

在现有WTP阈值下，与氟唑帕利单药方案相比，氟唑帕利联合阿帕替尼方案用于我国伴有胚系

BRCA1/2

突变的HER2－转移性乳腺癌患者的二线及后线治疗更具经济性。

Abstract

OBJECTIVE

To evaluate the cost-effectiveness of fluzoparib monotherapy versus combination with apatinib as second-line or later-line treatment for patients with germline

BRCA1

-mutated human epidermal growth factor receptor 2-negative （HER2－） metastatic breast cancer， from the perspective of the Chinese healthcare system.

METHODS

Based on the FABULOUS trial， a partitioned survival model was developed to simulate disease progression， with a cycle length of 21 days and a time horizon of 10 years. A discount rate of 4.5% per annum was applied. Model outputs included total costs and quality-adjusted life years （QALYs）. Cost-utility analysis was conducted by comparing the incremental cost-effectiveness ratio （ICER） between the two regimens against a willingness-to-pay （WTP） threshold set at twice China’s per capita gross domestic product in 2025 （199 330 yuan/QALY）. Robustness of the base-case results was tested through one-way sensitivity analysis， probabilistic sensitivity analysis， and scenario analyses.

RESULTS

For patients with germline

BRCA1/2

-mutated HER2－ metastatic breast cancer， fluzoparib combination with apatinib provided greater health benefits （1.91 QALYs vs. 1.69 QALYs） and incurred lower total costs （1 634 119.3 yuan vs. 1 855 264.2 yuan） compared with fluzoparib monotherapy， thus representing a dominant strategy. One-way sensitivity and probabilistic sensitivity analyses confirmed the robustness of the base-case findings. Scenario analyses showed that the conclusion remained robust when the time horizon was shortened to 5 years or when the discount rate was changed to 3%； however， the results reversed when the extrapolation distribution model was altered.

CONCLUSIONS

Under the current WTP threshold， compared with fluzoparib monotherapy， the combination of fluzoparib and apatinib is more cost-effective as a second-line or later-line treatment for Chinese patients with germline

BRCA1

-mutated HER2－ metastatic breast cancer.

关键词

Keywords

references

Bray F ， Laversanne M ， Sung H ， et al . Global cancer statistics 2022：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J ] . CA Cancer J Clin ， 2024 ， 74 （ 3 ）： 229 - 263 .

Huppert L A ， Gumusay O ， Idossa D ， et al . Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer [J ] . CA Cancer J Clin ， 2023 ， 73 （ 5 ）： 480 - 515 .

Li H P ， Liu J Q ， Ouyang Q C ， et al . Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations（FABULOUS）：interim analysis of a multicentre，three-arm，open-label，randomised，phase 3 trial [J ] . Lancet Oncol ， 2025 ， 26 （ 12 ）： 1563 - 1574 .

Lim J J ， Yang K ， Taylor-Harding B ， et al . VEGFR3 inhibition chemosensitizes ovarian cancer stemlike cells through down-regulation of BRCA1 and BRCA2 [J ] . Neoplasia ， 2014 ， 16 （ 4 ）： 343-353.e1-2 .

Qin S K ， Li Q ， Gu S Z ， et al . Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma（AHELP）：a multicentre，double-blind，randomised，placebo-controlled，phase 3 trial [J ] . Lancet Gastroenterol Hepatol ， 2021 ， 6 （ 7 ）： 559 - 568 .

唐兰花，曾珊 . 《内分泌治疗后或HR－HER2－晚期乳腺癌化疗和靶向治疗：ASCO更新版指南》解读 [J ] . 肿瘤综合治疗电子杂志， 2021 ， 7 （ 4 ）： 43 - 48 . http：//dx.chinadoi.cn/10.12151/JMCM.2021.04-08 http://dx.chinadoi.cn/10.12151/JMCM.2021.04-08 .

Pujade-Lauraine E ， Selle F ， Scambia G ， et al . Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor（OReO/ENGOT-ov38）：a phase Ⅲb trial [J ] . Ann Oncol ， 2023 ， 34 （ 12 ）： 1152 - 1164 .

Wu H L ， Luo Z Y ， He Z L ， et al . All HER2-negative breast cancer patients need gBRCA testing：cost-effectiveness and clinical benefits [J ] . Br J Cancer ， 2023 ， 128 （ 4 ）： 638 - 646 .

吴晶，刘国恩 . 中国药物经济学评价指南：2025中英双语版 [M ] . 北京：中国计划出版社， 2025 ： 54 - 64 .

石丰豪，商叶，芮明军，等 . R语言survHE程序包在卫生经济学评价中的应用 [J ] . 中国卫生经济， 2020 ， 39 （ 9 ）： 9 - 14 .

Collett D . Modelling survival data in medical research [M ] . 3rd ed . London ： Chapman & Hall/CRC ， 2015 ： 76 - 78 .

闫文英，陶心悦，冯冰 . 特瑞普利单抗联合紫杉醇治疗转移性或复发性三阴性乳腺癌的成本-效果分析 [J ] . 中国药房， 2025 ， 36 （ 3 ）： 336 - 340 .

陈伟伟，侯艳红，杨劲，等 . 洛拉替尼对比伊鲁阿克一线治疗间变性淋巴瘤激酶阳性晚期非小细胞肺癌的成本-效用分析 [J ] . 中国医院药学杂志， 2026 ， 46 （ 3 ）： 301 - 306 .

张森，贾才凤，王洁，等 . 瑞波西利联合来曲唑一线治疗HR+/HER2－晚期或转移性乳腺癌的成本-效用分析 [J ] . 中国现代应用药学， 2025 ， 42 （ 19 ）： 3432 - 3439 .

蒋媛，朱盈盈，张惠娟 . 卡瑞利珠单抗联合阿帕替尼一线治疗晚期不可切除肝细胞癌的成本-效用分析 [J ] . 中国新药与临床杂志， 2024 ， 43 （ 4 ）： 273 - 279 .

张冉冉，张羽曦，高胜男，等 . 芦康沙妥珠单抗对比单药化疗用于转移性三阴性乳腺癌二线及后线治疗的成本-效果分析 [J ] . 中国药房， 2025 ， 36 （ 16 ）： 2024 - 2029 .

NCI . NCI common terminology criteria for adverse events（CTCAE）version 4.0 [EB/OL ] .（ 2021-07-25 ）[ 2026-04-01 ] . https：//ctep.cancer.gov/protocolDevelopment/electronic_ applications/ ctc.htm https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm .

甘肃省统计局，国家统计局甘肃调查总队 . 2025年甘肃省国民经济和社会发展统计公报 [EB/OL ] .（ 2026-03-13 ）[ 2026-04-01 ] . https：//tjj.gansu.gov.cn/tjj/c109457/202603/174305297.shtml https://tjj.gansu.gov.cn/tjj/c109457/202603/174305297.shtml .

Robson M ， Im S A ， Senkus E ， et al . Olaparib for metastatic breast cancer in patients with a germline BRCA mutation [J ] . N Engl J Med ， 2017 ， 377 （ 6 ）： 523 - 533 .

闫茜，赵曦，李宁，等 . 奥拉帕利治疗HER2阴性转移性乳腺癌的成本-效用分析 [J ] . 现代医学， 2023 ， 51 （ 5 ）： 604 - 610 .

Pan J J ， Ren N ， Ren L Q ， et al . Cost-effectiveness of talazoparib for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US [J ] . Sci Rep ， 2024 ， 14 （ 1 ）： 13935 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Pharmacoeconomic evaluation of culmerciclib combined with fulvestrant in the second-line treatment of HR+/HER2－ locally advanced or metastatic breast cancer

Cost-utility analysis of anlotinib combined with penpulimab in first-line treatment of unresectable hepatocellular carcinoma

Cost-utility analysis of rezivertinib versus gefitinib as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer

白蛋白结合型紫杉醇与溶剂型紫杉醇治疗转移性乳腺癌的最小成本分析

阿帕替尼联合全身化疗用于胃肠胰神经内分泌肿瘤肝转移的临床观察

Related Author

LIU Guoqiang

LIU Ziyi

WANG Yue

ZHANG Ranran

ZHANG Yuxi

LI Congxin

GAO Shengnan

LIU Ran

Related Institution

Dept. of Pharmacy， Hebei Medical University Third Hospital

School of Graduate， Hebei Medical University

Hebei Society for Integrated Drug and Health Technology Assessment

Dept. of Clinical Pharmacy， Hebei Medical University Third Hospital

Hebei Provincial Society for Integrated Drug and Health Technology Assessment

⁰

Cost-effectiveness analysis of fluzoparib monotherapy versus combination with apatinib in the treatment of germline BRCA1/2-mutated HER2-negative metastatic breast cancer

DOI：10.6039/j.issn.1001-0408.2026.14.11

摘要

Abstract

关键词

Keywords

references